Cargando…

Gadoxetate-enhanced dynamic contrast-enhanced MRI for evaluation of liver function and liver fibrosis in preclinical trials

BACKGROUND: To facilitate translational drug development for liver fibrosis, preclinical trials need to be run in parallel with clinical research. Liver function estimation by gadoxetate-enhanced dynamic contrast-enhanced MRI (DCE-MRI) is being established in clinical research, but still rarely used...

Descripción completa

Detalles Bibliográficos
Autores principales: Huh, Jimi, Ham, Su Jung, Cho, Young Chul, Park, Bumwoo, Kim, Bohyun, Woo, Chul-Woong, Choi, Yoonseok, Woo, Dong-Cheol, Kim, Kyung Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858707/
https://www.ncbi.nlm.nih.gov/pubmed/31729971
http://dx.doi.org/10.1186/s12880-019-0378-5
_version_ 1783471009413726208
author Huh, Jimi
Ham, Su Jung
Cho, Young Chul
Park, Bumwoo
Kim, Bohyun
Woo, Chul-Woong
Choi, Yoonseok
Woo, Dong-Cheol
Kim, Kyung Won
author_facet Huh, Jimi
Ham, Su Jung
Cho, Young Chul
Park, Bumwoo
Kim, Bohyun
Woo, Chul-Woong
Choi, Yoonseok
Woo, Dong-Cheol
Kim, Kyung Won
author_sort Huh, Jimi
collection PubMed
description BACKGROUND: To facilitate translational drug development for liver fibrosis, preclinical trials need to be run in parallel with clinical research. Liver function estimation by gadoxetate-enhanced dynamic contrast-enhanced MRI (DCE-MRI) is being established in clinical research, but still rarely used in preclinical trials. We aimed to evaluate feasibility of DCE-MRI indices as translatable biomarkers in a liver fibrosis animal model. METHODS: Liver fibrosis was induced in Sprague-Dawley rats by thioacetamide (200 mg, 150 mg, and saline for the high-dose, low-dose, and control groups, respectively). Subsequently, DCE-MRI was performed to measure: relative liver enhancement at 3-min (RLE-3), RLE-15, initial area-under-the-curve until 3-min (iAUC-3), iAUC-15, and maximum-enhancement (Emax). The correlation coefficients between these MRI indices and the histologic collagen area, indocyanine green retention at 15-min (ICG-R15), and shear wave elastography (SWE) were calculated. Diagnostic performance to diagnose liver fibrosis was also evaluated by receiver-operating-characteristic (ROC) analysis. RESULTS: Animal model was successful in that the collagen area of the liver was the largest in the high-dose group, followed by the low-dose group and control group. The correlation between the DCE-MRI indices and collagen area was high for iAUC-15, Emax, iAUC-3, and RLE-3 but moderate for RLE-15 (r, − 0.81, − 0.81, − 0.78, − 0.80, and − 0.51, respectively). The DCE-MRI indices showed moderate correlation with ICG-R15: the highest for iAUC-15, followed by iAUC-3, RLE-3, Emax, and RLE-15 (r, − 0.65, − 0.63, − 0.62, − 0.58, and − 0.56, respectively). The correlation coefficients between DCE-MRI indices and SWE ranged from − 0.59 to − 0.28. The diagnostic accuracy of RLE-3, iAUC-3, iAUC-15, and Emax was 100% (AUROC 1.000), whereas those of RLE-15 and SWE were relatively low (AUROC 0.777, 0.848, respectively). CONCLUSION: Among the gadoxetate-enhanced DCE-MRI indices, iAUC-15 and iAUC-3 might be bidirectional translatable biomarkers between preclinical and clinical research for evaluating histopathologic liver fibrosis and physiologic liver functions in a non-invasive manner.
format Online
Article
Text
id pubmed-6858707
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68587072019-11-29 Gadoxetate-enhanced dynamic contrast-enhanced MRI for evaluation of liver function and liver fibrosis in preclinical trials Huh, Jimi Ham, Su Jung Cho, Young Chul Park, Bumwoo Kim, Bohyun Woo, Chul-Woong Choi, Yoonseok Woo, Dong-Cheol Kim, Kyung Won BMC Med Imaging Research Article BACKGROUND: To facilitate translational drug development for liver fibrosis, preclinical trials need to be run in parallel with clinical research. Liver function estimation by gadoxetate-enhanced dynamic contrast-enhanced MRI (DCE-MRI) is being established in clinical research, but still rarely used in preclinical trials. We aimed to evaluate feasibility of DCE-MRI indices as translatable biomarkers in a liver fibrosis animal model. METHODS: Liver fibrosis was induced in Sprague-Dawley rats by thioacetamide (200 mg, 150 mg, and saline for the high-dose, low-dose, and control groups, respectively). Subsequently, DCE-MRI was performed to measure: relative liver enhancement at 3-min (RLE-3), RLE-15, initial area-under-the-curve until 3-min (iAUC-3), iAUC-15, and maximum-enhancement (Emax). The correlation coefficients between these MRI indices and the histologic collagen area, indocyanine green retention at 15-min (ICG-R15), and shear wave elastography (SWE) were calculated. Diagnostic performance to diagnose liver fibrosis was also evaluated by receiver-operating-characteristic (ROC) analysis. RESULTS: Animal model was successful in that the collagen area of the liver was the largest in the high-dose group, followed by the low-dose group and control group. The correlation between the DCE-MRI indices and collagen area was high for iAUC-15, Emax, iAUC-3, and RLE-3 but moderate for RLE-15 (r, − 0.81, − 0.81, − 0.78, − 0.80, and − 0.51, respectively). The DCE-MRI indices showed moderate correlation with ICG-R15: the highest for iAUC-15, followed by iAUC-3, RLE-3, Emax, and RLE-15 (r, − 0.65, − 0.63, − 0.62, − 0.58, and − 0.56, respectively). The correlation coefficients between DCE-MRI indices and SWE ranged from − 0.59 to − 0.28. The diagnostic accuracy of RLE-3, iAUC-3, iAUC-15, and Emax was 100% (AUROC 1.000), whereas those of RLE-15 and SWE were relatively low (AUROC 0.777, 0.848, respectively). CONCLUSION: Among the gadoxetate-enhanced DCE-MRI indices, iAUC-15 and iAUC-3 might be bidirectional translatable biomarkers between preclinical and clinical research for evaluating histopathologic liver fibrosis and physiologic liver functions in a non-invasive manner. BioMed Central 2019-11-15 /pmc/articles/PMC6858707/ /pubmed/31729971 http://dx.doi.org/10.1186/s12880-019-0378-5 Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Huh, Jimi
Ham, Su Jung
Cho, Young Chul
Park, Bumwoo
Kim, Bohyun
Woo, Chul-Woong
Choi, Yoonseok
Woo, Dong-Cheol
Kim, Kyung Won
Gadoxetate-enhanced dynamic contrast-enhanced MRI for evaluation of liver function and liver fibrosis in preclinical trials
title Gadoxetate-enhanced dynamic contrast-enhanced MRI for evaluation of liver function and liver fibrosis in preclinical trials
title_full Gadoxetate-enhanced dynamic contrast-enhanced MRI for evaluation of liver function and liver fibrosis in preclinical trials
title_fullStr Gadoxetate-enhanced dynamic contrast-enhanced MRI for evaluation of liver function and liver fibrosis in preclinical trials
title_full_unstemmed Gadoxetate-enhanced dynamic contrast-enhanced MRI for evaluation of liver function and liver fibrosis in preclinical trials
title_short Gadoxetate-enhanced dynamic contrast-enhanced MRI for evaluation of liver function and liver fibrosis in preclinical trials
title_sort gadoxetate-enhanced dynamic contrast-enhanced mri for evaluation of liver function and liver fibrosis in preclinical trials
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858707/
https://www.ncbi.nlm.nih.gov/pubmed/31729971
http://dx.doi.org/10.1186/s12880-019-0378-5
work_keys_str_mv AT huhjimi gadoxetateenhanceddynamiccontrastenhancedmriforevaluationofliverfunctionandliverfibrosisinpreclinicaltrials
AT hamsujung gadoxetateenhanceddynamiccontrastenhancedmriforevaluationofliverfunctionandliverfibrosisinpreclinicaltrials
AT choyoungchul gadoxetateenhanceddynamiccontrastenhancedmriforevaluationofliverfunctionandliverfibrosisinpreclinicaltrials
AT parkbumwoo gadoxetateenhanceddynamiccontrastenhancedmriforevaluationofliverfunctionandliverfibrosisinpreclinicaltrials
AT kimbohyun gadoxetateenhanceddynamiccontrastenhancedmriforevaluationofliverfunctionandliverfibrosisinpreclinicaltrials
AT woochulwoong gadoxetateenhanceddynamiccontrastenhancedmriforevaluationofliverfunctionandliverfibrosisinpreclinicaltrials
AT choiyoonseok gadoxetateenhanceddynamiccontrastenhancedmriforevaluationofliverfunctionandliverfibrosisinpreclinicaltrials
AT woodongcheol gadoxetateenhanceddynamiccontrastenhancedmriforevaluationofliverfunctionandliverfibrosisinpreclinicaltrials
AT kimkyungwon gadoxetateenhanceddynamiccontrastenhancedmriforevaluationofliverfunctionandliverfibrosisinpreclinicaltrials